Gastrointestinal stromal tumours - imatinib (adjuvant) (TA196)
NICE does not recommend imatinib as an adjuvant treatment for people after surgical removal of a GIST.
There is not enough evidence from clinical trials to say how well imatinib works as an adjuvant treatment, or whether it works well enough to justify its cost, so NICE did not recommend it.
Results from some clinical trials of imatinib as an adjuvant treatment after surgical removal of a GIST are due soon, and NICE will look at this evidence when it becomes available.
NICE looks at how well treatments work, and also at how well they work in relation to how much they cost the NHS. NICE applies special considerations to treatments that can extend the lives of people who are nearing the end of their life.
- TA196 Gastrointestinal stromal tumours - imatinib (adjuvant): review decision - December 2012
- TA196 Gastrointestinal stromal tumours - imatinib (adjuvant): review proposal - October 2012
- Gastrointestinal stromal tumours - imatinib (adjuvant): review update - June 2011
- Gastrointestinal stromal tumours - imatinib (adjuvant): press release
This page was last updated: 27 November 2012
- Web format
- Quick reference guide (PDF)
- NICE Guidance (PDF)
- TA196 Imatinib fel triniaeth gynorthwyol ar gyfer tiwmorau stromatig gastro-berfeddol (GISTau) ar ôl llawdriniaeth: Deall canllawiau NICE (fformat MS Word)
Information for the public
Implementation tools and resources
See this guidance in practice
The summary of the key recommendations in the guidance written for patients, carers and those with little medical knowledge and may be used in local patient information leaflets.
Quick Reference Guide
The quick reference guide presents recommendations for health professionals
The published NICE clinical guidance, contains the recommendations for health professionals and NHS bodies.
The published full clinical guidance for specialists with background, evidence, recommendations and methods used.